RSI-MRI+ is FDA-cleared post-processing software that supports improved detection of clinically significant prostate cancer.
Leveraging an advanced diffusion MRI technique called Restriction Spectrum Imaging, powered by AI, the software enables faster, more accurate PI-RADS scoring.
Shows areas of restricted diffusion with increased conspicuity compared to high b-value DWI.
Automatically fuses the colorized Restricted Signal Map with the T2-weighted image series to support anatomical localization.
The first commercial imaging software to use an advanced multi-compartment diffusion model, RSI-MRI+ better interrogates prostate tissue microstructure to improve conspicuity of restricted diffusion.
RSI-MRI+ provides a unique characterization of the restricted signal component — called the Restricted Signal Map — which improves visualization and quantification of restricted water compared to standard diffusion-weighted imaging (DWI).